Denosumab: a review of its use in postmenopausal women with osteoporosis.

Abstract

Subcutaneous denosumab (Prolia(®) [USA, Europe]; Pralia(®) [Japan]) once every 6 months is indicated in several countries for the treatment of postmenopausal women with osteoporosis at increased or high risk for fractures (featured indication). In some countries, it is also indicated for use in postmenopausal women who have failed or are intolerant to other osteoporosis treatments. In several international, phase III trials (≤3 years' duration) involving more than 12,000 women with postmenopausal osteoporosis or low bone mineral density (BMD), including Asian studies, denosumab was an effective and generally well tolerated treatment. Relative to placebo, denosumab treatment significantly reduced the risk of vertebral, nonvertebral and hip fractures and increased BMD at all skeletal sites evaluated, including the lumbar spine and total hip. Furthermore, the benefits of denosumab treatment were generally evident after the first dose and were maintained during up to 8 years of treatment in an ongoing extension study. The tolerability profile of denosumab during this extension phase was consistent with that observed during the initial 3-year FREEDOM trial. At 12 months, denosumab treatment increased BMD at the total hip, lumbar spine and/or femoral neck and reduced markers of bone turnover to a significantly greater extent than oral bisphosphonates in women who were essentially bisphosphonate-naive and in those who had switched from alendronate to denosumab treatment. Further clinical experience, including an ongoing postmarketing safety study, will more fully define the long-term safety of denosumab. In the meantime, denosumab is an important option for the treatment of women with postmenopausal osteoporosis at increased or high-risk of fractures, including in women at increased risk of fracture who are unable to take other osteoporosis treatments.

• Authors: Lesley J Scott
• Journal: Drugs & aging (Drugs Aging) Vol. 31 Issue 7 Pg. 555-76 (Jul 2014) ISSN: 1179-1969 [Electronic] New Zealand
• PMID: 24935243 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• RANK Ligand
• TNFSF11 protein, human
• Denosumab

Topics

• Antibodies, Monoclonal, Humanized (adverse effects, economics, pharmacology, therapeutic use)
• Denosumab
• Female
• Humans
• Osteoporosis, Postmenopausal (drug therapy, economics, metabolism)
• RANK Ligand (antagonists & inhibitors)